anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine; pharmaceuticals.SUBSTANCE: group of invention refers to pharmaceutical industry, namely to a method for preparing an agent for treating or preventing Alzheimer's disease. Method of producing an agent for treating or preventing Alzheimer's disease, wherein said agent contains an earthworm extract extracted with water or aqueous ethanol, and/or dry powder of said extract, wherein said method comprises the following steps of preparing the extract: bringing live worm earthworm into contact with a chloride of at least one metal selected from a group consisting of potassium, sodium, magnesium and calcium; further bringing live worm into contact with powdered form of hydroxycarboxylic acid, diluted with water to bring pH from 2 to 5, and maintaining the obtained dilution for 3 to 180 minutes, or immersing and holding the live earthworm for 3 to 180 minutes in an aqueous solution of hydroxycarboxylic acid, having a pH value of from 2 to 5, washing the living earthworm with water, grinding the live earthworm and then lyophilisation of the obtained milled product; heating the lyophilized ground product at temperature of 110 °C or higher but lower than 130 °C, and dissolving said thermally treated product in water or in aqueous ethanol solution with ethanol concentration of 70 % or lower and then removing or separating insoluble fractions, where earthworm is red earthworm Lumbricus rubellus. Agent for treating or preventing Alzheimer's disease. Earthworm extract for stimulating catecholamine production. Use of an earthworm extract for treating Alzheimer's disease. Method of treating or preventing Alzheimer's disease.EFFECT: above described solutions enable prevention and treatment of diseases caused by catecholamine deficiency.5 cl, 4 dwg
Participants with eGFR ≥ 70 mL/min/1.73 m\^2 received one 130 mg dose of MB-102 and a transdermal sensor was placed on their chest. Blood samples and fluorescent measurements were collected over 12 hours.
The duration of the neoadjuvant treatment period is planned to be 12 weeks (4 cycles of 3 weeks), except in case of Inacceptable toxicity, or Patient decision, or Withdrawal of consent, or Clinical/radiological signs of disease progression.This neoadjuvant treatment period will be ended with a short term safety visit (STSVNeo) to be scheduled 28 days after the last dose of study treatments (considering the latest study treatments administered). Following the STSVNeo, patients will undergo surgery as per usual practice and pathological response will be centrally assessed by a referent pathologist blinded for the treatment arms.Following surgery, all patients will be treated in the adjuvant setting with trastuzumab administered every 3 weeks for up to 12 months in both arms with clinical assessments every 3 months (cf. Réseau régional de Cancérologie, http://espacecancer.sante-ra.fr/Pages/Accueil.aspx). In case of RH+ disease, endocrine therapy may be initiated as per standard treatment guidelines.This adjuvant treatment period is planned for a maximum of 12 months; except in case of Inacceptable toxicity, or Patient decision, or Withdrawal of consent, or Clinical/radiological signs of disease progression. All randomized and treated patients will be followed-up for relapse and survival for at least 15 months post-randomization (i.e. 1 year post-surgery).

A total of 90 patients will be randomized in the study. (45 per arm). All the data concerning the patients will be recorded in the electronic case report form (eCRF) throughout the study serious adverse event (SAE) reporting will be also paper-based by e-mail and/or Fax. The sponsor will perform the study monitoring and will help the investigators to conduct the study in compliance with the clinical trial protocol, Good Clinical Practices (GCP) and local law requirements
A convenience sample will be used to obtain subjects The subjects will be recruited through posted advertisements on social networks. The inclusion and exclusion criteria will be applied to the volunteers. The sample wil comprise university students and administrative workers with neck pain. The subjects will be screened by a screening questionnaire and all of them, they will be required to sign an inform consent before participating to the study. After signing it, they will be randomly divide into control group subject to a placebo technique and the intervention group subject to an active mobilization of the sciatic nerve.

To assess changes in cervical articular range, will be used, a cervical goniometer (CROM) and for changes in pressure pain threshold of the trigger points will be used a mechanical algometer. Furthermore, to asses changes in pain perception will be used a visual numerical scale. The statistical analysis will be performed using the statistical program SPSS 25.0, comparing the results between both groups.
Given the rapid growth in educational policies targeting educators' knowledge of dyslexia, this study explored the technical adequacy of a common instrument for measuring that knowledge. The responses of 1141 preservice teachers were scored in three ways: polytomously with the original 4-point Likert scale, dichotomously as true-false, and dichotomously as though the options were multiple choice. An exploratory factor analysis suggested at least one-third of the items needed to be removed. Confirmatory factor analyses suggested a one-factor model with polytomous scoring had the best fit to the data, but only six items loaded. All models demonstrated unacceptable internal consistency reliability (<0.70). Because no technically adequate version of the measure was identified, questions remain about basing policy on scores from these instruments. However, the findings indicated ways this type of measure might be improved.
The invention provides an ecological flexible typed non-basic fat dissolving agent, is a cleaning article for dissolving fat and eliminating fat pollution. The main technical characteristics are as follows: the plant physiological tissues in a normal dry growth state in the late stage of being rooted in the soil are adopted as raw material. When the plant physiological tissues are extruded by hand or nail at will, no obvious movable sap is exuded. After impurities are properly removed, the pH valve shall be equal to or less than 7 when the plant physiological tissues are soaked in clear water for a short time. The plant physiological tissues have no side effect to human skin. All kinds of plant physiological tissues series products are made by processing the plant physiological tissues by adopting the technologies of manpower or machine decomposition and thinning, purification and liquid taking, sterilization, anti-corrosion treatment, dehydration treatment, batch sub-package, and moisture or supplementary materials allocation and so on. The ecological flexible typed non-basic fat dissolving agent removes or cleans all kinds of mineral and biological fat pollution in a dissolving way, can be widely used for the alkali-free fat-dissolving cleaning operations in all kinds of science and technology fields, is suitable to be used for the large area dry bath of human skin and cleaning the fat pollution around a wound.
Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
Lumina Dermal Filler injected into 1 nasolabial fold. Optional Touch-up at 3 week visit with same.
Participants undergoing other reconstructive surgery for bone neoplasm. Study visits for post-op assessments will be annually after month-36.
The present disclosure relates to a combination therapy with an anti-Trophoblast cell surface antigen 2 (Trop-2) antibody drug conjugate (anti-Trop-2 ADC) and a poly (ADP-ribose) polymerase inhibitor (PARPi) using a staggered dosing schedule. The ADC preferably incorporates an inhibitor of type I topoisomerase, such as SN-38 or DXd. The ADC is preferably administered prior to the PARPi in each cycle of the staggered dosing schedule. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies. The schedules and dosages show efficacy against tumors, while exhibiting only manageable toxicity to normal tissues. Use of staggered dosing of an anti-Trop-2 ADC and a PARPi can reduce toxicity, for example relative to alternative dosing schedules involving daily administrations of the PARPi on each day of a cycle.
The invention relates to a GDNF gene-polycation nano-particle composition, a preparation method and an application thereof. The nano-particle composition comprises a GDNF gene substance and polycation. The polycation is polyspermineimidazole-4,5-diimine or polyspermineimidazole-4,5-diamide. A mass ratio of the polycation to the GDNF gene substance is 5-100. The nano-particle composition is less in toxin, is high in transfection efficiency, can achieve both stability before arriving a target cell and a biologically-responsibility after entering the target cell during an in-vivo circulation process. Polycation itself can be metabolized toxic-free in-vivo so that the nano-particle composition can be used for treating Parkinson's disease and complications thereof through intracranially local injection.
This is a group that will receive mindfulness intervention for 14 days. Participants in this group will also be asked baseline, daily and post questions, as well as follow up questions (3 months after the intervention). During the intervention, they can fill out an optional daily journal.
Purified intrinsic factor preparations are obtained by treating a concentrate with intrinsic factor activity, in the presence of Vitamin B12, in an aqueous system which contains 35-50 per cent by volume of an alkanol or alkanone with not more than three carbon atoms, and separating the resulting liquid phase which contains the active constituent.  For example, methanol, ethanol, isopropanol, propanol and acetone may be employed. Preferably the treatment is effected in the presence of one or more salts, e.g. sodium chloride, at a pH 6-7, and at 0 DEG  C. or at a lower temperature.  Extra purification may be obtained by increasing the alkanol or alkanone concentration to a value ranging from 60-75 per cent by vol.  The product comprising I.F. activity-containing compound with bound Vitamin B12 is useful in the treatment of pernicious anaemia. Specification 733,875 is referred to.
Participants with selected types of advanced and/or metastatic tumors will receive the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) (determined from Parts 1 and 2) of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label). Treatment will be administered for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
High-grade gliomas are the most common brain tumors in humans and are essentially incurable. The defining hallmark of these high-grade gliomas is the presence within the tumor mass of highly tumorigenic cellular subpopulations that fuel tumor aggressiveness. Identification of the molecular mechanisms remains elusive. Therefore, there is a need for diagnostic markers to accurately determine the type of glioma and appropriate treatment. Gene delivery vehicles are provided that comprise an oncogene, IRES-Cre-ER cassette and a gene encoding an oligonucleotide that inhibits p53 including shp53. Methods are also provided for determining a diagnosis and for treatment of non-aggressive and aggressive gliomas.
The invention relates to application of eutelone in preparing a pancreatic cancer drug, wherein the eutelone inhibits pancreatic cancer. The medicine can inhibit pancreatic cancer proliferation. The proliferation is cell growth or clone formation. The pancreatic cancer is primary pancreatic cancer or secondary pancreatic cancer. The medicine contains effective therapeutic amount of the eudragit and a pharmaceutically acceptable carrier. The invention discovers that the eutelone can inhibit the proliferation of pancreatic cancer for the first time. The eutelone can obviously inhibit the activity of pancreatic cancer cell lines PANC-1 and BxPC-3, inhibit the clone formation, induce the cycle retardation and promote the apoptosis.
Acute limb ischemia (ALI) is defined as a sudden reduction in blood flow to a limb, resulting in cessation of blood flow and, therefore, cessation of the delivery of nutrients and oxygen to the tissues of the lower limb. Despite optimal treatment to restore blood flow to ischemic tissues, some patients may suffer from ischemia/reperfusion (I/R) syndrome, the most severe complication after a revascularization procedure used to restore blood flow. There are multiple molecular and cellular factors that are involved in each phase of ALI. This review focuses firstly on molecular and cellular factors of arterial thrombosis, highlighting the role of atherosclerotic plaques, smooth muscle cells (SMCs), and cytokine which may alter key components of the extracellular matrix (ECM). Then, molecular and cellular factors of arterial embolism will be discussed, highlighting the importance of thrombi composition. Molecular and cellular factors of ischemia/reperfusion syndrome are analyzed in depth, highlighting several important mechanisms related to tissue damage, such as inflammation, apoptosis, autophagy, necrosis, and necroptosis. Furthermore, local and general complications of ALI are discussed in the context of molecular alterations. Ultimately, the role of novel biomarkers and targeted therapies is discussed.
BACKGROUND: Periodontitis, a persistent inflammatory condition, significantly impairs individuals' overall quality of life. Lymphocyte-to-high-density lipoprotein cholesterol ratio (LHR), monocyte-to-high-density lipoprotein cholesterol ratio (MHR), neutrophil-to-high-density lipoprotein cholesterol ratio (NHR), and platelet-to-high-density lipoprotein cholesterol ratio (PHR) are new convenient and economical biomarkers. However, whether the above high-density lipoprotein-related inflammatory biomarkers are associated with periodontitis has rarely been investigated. Therefore, the research endeavor focused on uncovering potential relationships.
METHODS: The research encompassed a diverse and extensive sample, comprising 9,470 participants, selected from the National Health and Nutrition Examination Survey spanning the years 2009 to 2014. The association between high-density lipoprotein-related inflammatory biomarkers and periodontitis was explored utilizing a multivariable logistic regression model with weighted analysis. Additionally, the study employed smoothed curve fitting to explore potential nonlinear relationships. Further stratified analyses and interaction tests were performed.
RESULTS: This study indicated no apparent association between MHR and PHR with periodontitis, whereas LHR and NHR demonstrated a statistically significant positive relationship with the prevalence of periodontitis. In the fully adjusted model, participants belonging to the highest tertile of both LHR and NHR showed a notably higher likelihood of having periodontitis compared to those in the lowest tertile (LHR: OR = 1.22, 95% CI: 1.06, 1.39; NHR: OR = 1.27, 95% CI: 1.09, 1.49). Furthermore, smooth curve fitting was employed to investigate the potential nonlinear relationship between LHR, NHR, and periodontitis. The results indicated that there was a significant increase in the occurrence of periodontitis when Log2 (LHR) exceeded 1.01 and Log2(NHR) surpassed 2.16 (Log2(LHR): OR = 1.42; 95% CI: 1.19, 1.69; Log2(NHR): OR = 1.40; 95% CI: 1.15, 1.71). The subgroup analysis revealed that the associations between periodontitis and either LHR or NHR, separately, were more pronounced among individuals under the age of 50 and those without hypertension.
CONCLUSIONS: This cross-sectional study revealed a positive relationship between LHR、NHR and periodontitis, particularly when these indicators exceeded their thresholds. LHR and NHR may serve as potential inflammatory markers for identifying periodontitis, thereby facilitating early warning for both patients and dentists, and enabling early intervention in the oral environment. Besides, extensive prospective cohort investigations are essential to confirm and solidify this observation.
. The invention concerns a soluble encapsulated dietetic composition for oral or rectal administration. The invention is characterised in that said composition contains oil produced by cold mixing and pressing, under high pressure, of unhulled seeds of Cynara Carbunculus or of Silybum Marianum, in a proportion between 0.5 % and 100 %. In a preferred embodiment, each capsule comprises 500 mg of Cynara Carbunculus or Silybum Marianum oil. In such case, the composition may be administered to n adult being treated in doses of two to three capsules per day. Advantageously, the capsules are packaged in lots of 30, 60, 90 and 120 capsules, each lot generally corresponding to a standard treatment.
The present invention provides an amphiphilic phthalocyanine-based compound and metal chelates and salts thereof, wherein said compound possesses four peripheral ring systems in which one of said ring systems is more hydrophilic and has more hydrophilic group(s) than any one of the three remaining ring systems. Thus the compounds may be of formula (I) (wherein each of X<1>, X<2>, X<3> and X<4> together with the intervening ring carbon atoms independently represents an optionally substituted mono-, bi- or tri-cyclic aromatic or heteroaromatic ring system; with the provisos that (i) X<1> is linked via one or more linker groups, L, to at least one hydrophilic group wherein said hydrophilic group(s) together consists of, or contains, two or more groups which have a pKa < 4.0 when attached at position 5 on isoindole, and that (ii) where substituted, any ring system X<2>, X<3>, or X<4> is less hydrophilic than the ring system X<1>; and each L, which may be the same or different, represents a bond or an organic linker group). The hydrophilic group present in the ring system X<1> is preferably selected from the radicals of sulfonic acids, phosphonic acids, phosphoric acids, carboxylic acids, mono sulfate amides, mono phosphate amides and groups which result in sulfate or phosphate esters on attachment to the ring structure. Such compounds may be used as photosensitizing agents in photodynamic therapy (PDT, eg photochemotherapy), diagnosis, or may be used to introduce a transfer molecule into the cytosol of a cell (photochemical internalisation). Thus such compounds may be used in gene therapy or to treat cancer, rheumatoid arthritis, cardiovascular diseases (eg atherosclerosis) infections (eg viral), skin disorders (eg psoriasis, acne and abrasions) solar keratosis, wound healing, fracture healing, warts, inherited genetic disorders (eg cystic fibrosis), Gorlin's syndrome or ataxia telangiectasia. Pharmaceutical compositions and kits comprising such compounds are also disclosed.
The invention discloses a plant composition for skin beauty and chloasma removal, a preparation method and application thereof. The invention comprises the following main raw materials: saffron, red sage root, coix seed, tuckahoe, liquorice root. The functional components are as follows: each 100g of the composition contains 1130mg of total flavone, 1020mg of crude polysaccharide and 220mg of glycyrrhizic acid. The formula is developed by combining the theory of health care of modern Chinese medicine and the experience of improving or eliminating skin pigment spots under the guidance of the traditional Chinese medicine theory and the theory of 'integrating doctor with food'. Saffron and salvia activate blood and nourish blood; the coix seed and the tuckahoe have the functions of invigorating spleen and eliminating dampness; glycyrrhrizae radix has effects of removing toxic substance and resisting allergy. The advantages are that: regulating blood circulation and microcirculation, enhancing immunity, clearing away heat and toxic materials, promoting blood circulation, removing speckle, nourishing blood, caring skin, regulating metabolism, and resisting aging. The food has good remarkable effect of beautifying and removing chloasma, and has no adverse reaction after long-term administration. The process flow is simple and convenient to prepare, has no pollution, and is a safe and reliable health food for beautifying the face and removing the chloasma.
Accumulation of oxidized low-density lipoproteins in the intimae of arteries together with risk factors known to enhance atherosclerosis, damage the endothelium of the arterial wall. Dysfunction of the endothelium leads into loss of elasticity of the artery. Especially a reduction in the elasticity of small arteries has been found prominent in atherosclerosis and is believed to serve as a marker for early stages of atherosclerosis.

In this study, we investigate whether the levels of oxidized LDL and arterial elasticity differ between patients with metabolic syndrome and their physically active controls. Oxidized LDL is assessed by a two-site ELISA immunoassay (Mercodia, Uppsala, Sweden). The capacitive elasticity of large arteries (C1) and the reflective elasticity of small arteries (C2) are automatically assessed by the CR-2000 as a mean of five most similar pulse waves appearing during the measurement. C1 identifies the elastic properties of aorta and other large arteries, C2 the endothelial function of the microvascular circulation. Proper statistical methods are used to reveal possible differences and their significance between the patients and controls.
NEW MATERIAL:A synthetic polypeptide having an amino acid sequence of the formula, etc., and having an antigen-decision base common to hepatitis C virus. EXAMPLE:A reagent for hepatitis C virus (HCV) analysis. PREPARATION:A C-terminal amino acid alpha-amino group of which is protected, Boc-leucine (Boc is t-butyloxycarbonyl) is reacted in the presence of carbodiimide, e.g. by solid-phase synthesis using an oxymethyl resin as a carrier and the protective group for alpha-amino group is subsequently removed. Protected amino acids are then bonded in accordance with the amino acid sequence of a polypeptide and removal of the protective groups for alpha-amino groups are subsequently repeated so as to synthesize a polypeptide resin. The resultant polypeptide resin is treated with HF in anisole so that elimination of the polypeptide from the carrier resin and removal of the whole protective groups may be carried out, thus obtaining the objective polypeptide of the formula, etc.
Rheumatoid arthritis (RA) is a systemic immune-mediated disease that, in addition to the articular involvement, can have extra-articular manifestations. Even though liver damage in RA is not very common, associated autoimmune liver diseases (AILDs) may occur. The most common AILD associated with RA is primary biliary cirrhosis (PBC), followed by autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC). There are common underlying mechanisms that play a role in the emergence of autoimmunity and inflammation in both rheumatic and autoimmune liver diseases. Genetic studies have revealed the existence of several common disease-associated genes shared between RA and AILDs, and infectious triggers, particularly those associated with recurrent or complicated urinary tract infections, are also speculated to be potential triggers for these conditions. Moreover, these diseases share common serologic patterns characterized by the presence of specific autoantibodies and hyper-gammaglobulinemia. In this study, we focus on reviewing the association between RA and AILDs regarding the prevalence and possible etiopathogenic link.